AZTA vs. IDYA, APGE, ACLX, TMDX, ARWR, LIVN, AMED, LTH, IMCR, and BRC
Should you be buying Azenta stock or one of its competitors? The main competitors of Azenta include IDEAYA Biosciences (IDYA), Apogee Therapeutics (APGE), Arcellx (ACLX), TransMedics Group (TMDX), Arrowhead Pharmaceuticals (ARWR), LivaNova (LIVN), Amedisys (AMED), Life Time Group (LTH), Immunocore (IMCR), and Brady (BRC).
IDEAYA Biosciences (NASDAQ:IDYA) and Azenta (NASDAQ:AZTA) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation.
IDEAYA Biosciences has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Azenta has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.
98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 99.1% of Azenta shares are owned by institutional investors. 5.0% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 1.8% of Azenta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
IDEAYA Biosciences received 94 more outperform votes than Azenta when rated by MarketBeat users. Likewise, 67.47% of users gave IDEAYA Biosciences an outperform vote while only 38.30% of users gave Azenta an outperform vote.
In the previous week, IDEAYA Biosciences and IDEAYA Biosciences both had 4 articles in the media. IDEAYA Biosciences' average media sentiment score of 1.59 beat Azenta's score of 0.30 indicating that Azenta is being referred to more favorably in the news media.
IDEAYA Biosciences presently has a consensus price target of $46.60, suggesting a potential upside of 21.86%. Azenta has a consensus price target of $69.60, suggesting a potential upside of 35.49%. Given IDEAYA Biosciences' higher possible upside, analysts clearly believe Azenta is more favorable than IDEAYA Biosciences.
Azenta has a net margin of -2.92% compared to Azenta's net margin of -483.05%. IDEAYA Biosciences' return on equity of 0.49% beat Azenta's return on equity.
Azenta has higher revenue and earnings than IDEAYA Biosciences. Azenta is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Azenta beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks.
Get Azenta News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AZTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
